Vaccines Analysis
🌏 NMPAExpert commentary and market intelligence for pharma strategy teams
Showing 1–3 of 3 articles
Earlier
High impact AnalysisJun 2, 2026
Executive Order Challenges Childhood Vaccine Schedule: Pharma Implications
8 min
Dr. Yuki TanakaHigh impact AnalysisJun 2, 2026
Shionogi's Xocova Gains FDA Clearance for COVID-19 Post-Exposure Prevention
FDA · COVID-19 · 7 min
Dr. Sarah MitchellHigh impact AnalysisJun 2, 2026
Executive Order Targets Childhood Vaccine Schedule: What Pharma Needs to Know
8 min
Dr. Elena RossiExplore intelligence